Lasa , ICT explore Favipiravir therapy for Coronavirus, to apply to DCGI
Mumbai: Lasa Supergenerics Ltd In collaboration with Institute of Chemical Technology (ICT) recently announced commencement for Development of antiviral Compound Favipiravir as Covid19 Treatment.
Commenting on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said: "Health and safety of our countrymen are of pristine importance and to safeguard them from deadly corona we have joined hands with one of Government recognised Institute in India "Institute of Chemical Technology" to develop Favipiravir for Treatment of "COVID19" which has currently emerged as a pandemic."
"We are working together with all our efforts to commence the research and scale-up activity of Favipiravir, an antiviral drug, showing its promising activity for inhabitation of a wide range of viruses, we will take necessary steps for getting permission from Drug Controller General of India to Launch product in Indian Market at the earliest" he stated
"Once the Favipiravir therapy is approved by global regulatory authorities we would approach DCGI for conducting required bioequivalence clinical trials in India and also seek strategic private investments and/or Government aid to commercialise this the product subject to all regulatory approvals and trials" he further stated
Institute of Chemical Technology (ICT) Formerly the University Department of Chemical Technology (UDCT) is a Public deemed University specialized in Chemical Technology located in Mumbai, India. It is focused on training and research in various branches of chemical engineering, chemical technology and pharmacy.
Commenting on the Collaboration, Dr Vikas Terlvekar, Professor– Institute of Chemical Technology (ICT) said, "We appreciate this great step by Lasa Supergenerics Ltd and Dr.Omkar which shall help the nation and support the government to treat this deadly Covid-19, we have accepted the challenge to fight against the virus with each other's support and expect to succeed the battle".